Stereotaxis (STXS) – StreetInsider.com Reports
-
Stereotaxis (STXS) Reports In-Line Q4 EPS, provides guidance
-
Stereotaxis (STXS) Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the US
-
Stereotaxis (STXS) PT Lowered to $3 at Lake Street Capital Markets
-
Roth/MKM Starts Stereotaxis (STXS) at Buy
-
Stereotaxis (STXS) PT Lowered to $3 at Lake Street Capital Markets
-
Stereotaxis (STXS) PT Lowered to $5 at Craig-Hallum
-
Stereotaxis (STXS) PT Lowered to $4 at B.Riley
-
Stereotaxis (STXS) Misses Q3 EPS by 1c
-
Stereotaxis (STXS) Reports In-Line Q2 EPS
-
Stereotaxis (STXS) and Abbott Combine Technologies in Integrated Procedures to Treat Arrhythmia Patients
-
Stereotaxis (STXS) Files $100M Mixed Shelf
-
Stereotaxis (STXS) Announces 91.22M Share Offering by Selling Stockholders
-
Stereotaxis (STXS), Abbott (ABT) Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms
-
Stereotaxis (STXS) Misses Q1 EPS by 2c
-
Stereotaxis (STXS) PT Lowered to $4 at Lake Street Capital Markets
-
Stereotaxis (STXS) PT Lowered to $5.50 at B.Riley
-
Stereotaxis (STXS) electrophysiology products have been approved for sale in UK
-
Stereotaxis (STXS) PT Lowered to $7 at Craig-Hallum
-
Stereotaxis (STXS) PT Lowered to $5 at Cowen
-
Aegis Capital Starts Stereotaxis (STXS) at Buy
-
Stereotaxis (STXS) Announces CE Mark Submission for Robotically Navigated MAGiC Ablation Catheter
-
B.Riley Starts Stereotaxis (STXS) at Buy
-
Stereotaxis (STXS) PT Lowered to $11.50 at Loop Capital
-
Stereotaxis (STXS) PT Lowered to $10 at Craig-Hallum
-
Stereotaxis (STXS) PT Lowered to $7 at Cowen
-
Stereotaxis (STXS) PT Lowered to $8 at Lake Street Capital Markets
-
UPDATE: Craig-Hallum Starts Stereotaxis (STXS) at Buy, Could Be the Next ISRG
-
UPDATE: Loop Capital Starts Stereotaxis (STXS) at Buy
-
Stereotaxis (STXS) Announces International Journal of Cardiology Publishes Data Demonstrating Superior Outcomes of Robotic Cardiac Ablation in Pediatric Patients
-
Spartan Capital Starts Stereotaxis (STXS) at Buy
-
Cowen Sees a Buying Opportunity for Stereotaxis (STXS) Investors After NDR, Reiterates Outperform Rating
-
Stereotaxis (STXS) PT Raised to $11 at Piper Sandler
-
Stereotaxis (STXS) PT Raised to $12 at Lake Street Capital Markets
-
Piper Sandler Starts Stereotaxis (STXS) at Overweight
-
Stereotaxis (STXS) PT Raised to $9.50 at Northland Capital Markets, Following Earnings
-
Northland Capital Markets Starts Stereotaxis (STXS) at Outperform
-
Stereotaxis (STXS) Announces $15 Million Common Stock Financing
-
UPDATE: Cowen Starts Stereotaxis (STXS) at Outperform
-
Lake Street Capital Markets Starts Stereotaxis (STXS) at Buy
-
Stereotaxis (STXS) Earns FDA Clearance and Announces U.S. Launch of Genesis Robotic Magnetic
-
Stereotaxis (STXS) Announces CFO Transition
-
Stereotaxis (STXS) gains FDA 510(k) clearance for Steerable Catheter Control System
-
Unusual 11 Mid-Day Movers 7/8: (DGLY) (EBIO) (CLWT) Higher; (JUNO) (TTOO) (LEDS) Lower
-
Stereotaxis (STXS) Reports Q1 Loss of $0.11
-
Stereotaxis (STXS) Receives Vmotion Suite-Related U.S. Patent
-
Stereotaxis (STXS) Ramps Higher Mid-Day on Volume
-
Stereotaxis (STXS) Announces Lund Study Validates Improved Long-Term Clinical Outcomes for Niobe ES
-
Stereotaxis (STXS) Regains Nasdaq Listing Compliance
-
Unusual 11 Mid-Day Movers 4/4: (VA) (OCX) (RKUS) Higher; (SUNE) (VCEL) (GBSN) Lower
-
Stereotaxis (STXS) Announces Enrollment Milestone Reached in Niobe System PMS Enrollment
Back to STXS Stock Lookup